Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2006 May-Jun;4(3):253-62.
doi: 10.1370/afm.517.

Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes

Gerald Gartlehner  1 , Richard A Hansen, Shannon S Carson, Kathleen N Lohr
Affiliations
Meta-Analysis

Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes

Gerald Gartlehner et al. Ann Fam Med. 2006 May-Jun.

Abstract

Purpose: We wanted to review systematically the efficacy, effectiveness, and safety of inhaled corticosteroids with respect to health outcomes in patients with chronic obstructive pulmonary disease (COPD).

Methods: We searched MEDLINE, EMBASE, The Cochrane Library, and the International Pharmaceutical Abstracts to identify relevant articles. We limited evidence to double-blinded randomized controlled trials (RCTs) for efficacy, but we also reviewed observational evidence for safety. Outcomes of interest were overall mortality, exacerbations, quality of life, functional capacity, and respiratory tract symptoms. When possible, we pooled data to estimate summary effects for each outcome.

Results: Thirteen double-blinded RCTs determined the efficacy of an inhaled corticosteroid compared with placebo; 11 additional studies assessed the safety of inhaled corticosteroid treatment in patients with asthma or COPD. Overall, COPD patients treated with inhaled corticosteroids experienced significantly fewer exacerbations than patients taking placebo (relative risk [RR] = 0.67; 95% CI, 0.59-0.77). No significant difference could be detected for overall mortality (RR = 0.81; 95% CI, 0.60-1.08). Evidence on quality of life, functional capacity, and respiratory tract symptoms is mixed. Adverse events were generally tolerable; pooled discontinuation rates did not differ significantly between inhaled corticosteroid and placebo treatment groups (RR = 0.92; 95% CI, 0.74-1.14). Observational evidence, however, indicates a dose-related risk of cataract and open-angle glaucoma. Severe adverse events, such as osteoporotic fractures, are rare; the clinical importance of the additional risk is questionable.

Conclusions: Overall, the risk-benefit ratio appears to favor inhaled corticosteroid treatment in patients with moderate to severe COPD. Existing evidence does not indicate a treatment benefit for patients with mild COPD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Results of literature search.
Figure 2.
Figure 2.
Relative risk meta-analysis of effects of inhaled corticosteroids on exacerbations. COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; MDI = metered dose inhaler.
Figure 2.
Figure 2.
Relative risk meta-analysis of effects of inhaled corticosteroids on exacerbations. COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; MDI = metered dose inhaler.
Figure 3.
Figure 3.
Relative risk meta-analysis of effects of inhaled corticosteroids: all-cause mortality. ICS = inhaled corticosteroid; COPD = chronic obstructive pulmonary disease.
Figure 3.
Figure 3.
Relative risk meta-analysis of effects of inhaled corticosteroids: all-cause mortality. ICS = inhaled corticosteroid; COPD = chronic obstructive pulmonary disease.
See this image and copyright information in PMC

Comment in

References

    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504. - PubMed
    1. National Center for Health Statistics. NCHS data on chronic obstructive pulmonary disorder. Available at: http://www.cdc.gov/nchs/data/factsheets/copd.pdf. Accessed: 22 September 2005.
    1. Fabbri LM, Hurd SS. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J. 2003;22:1–2. - PubMed
    1. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–679. - PubMed
    1. Pauwels R. Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass? Am J Respir Crit Care Med. 2002;165:1579–1580. - PubMed

Publication types

MeSH terms